Advertisement

Breast Cancer Symposium - Enhancing Clinical Care Through Collaboration

General Poster Session Abstracts

General Poster Session Abstracts

General Poster Session A  ♦  General Poster Session B  ♦  General Poster Session C


Poster Session A

Abstract # 98 : Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. ( A1 )
Mark D. Pegram , MD - University of Miami Sylvester Comprehensive Cancer Center


Abstract # 99 : Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial. ( A2 )
Francis P. Arena , MD - Arena Oncology Associates


Abstract # 1 : Prognostic impact of the 21-gene recurrence score (RS) on disease-free and overall survival of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: Results from NSABP B-28. ( A3 )
Eleftherios P. Mamounas , MD National Surgical Adjuvant Breast and Bowel Project and Aultman Hospital


Abstract # 2 : Correlation of receptor activator of nuclear factor kappa b (RANK) expression in breast cancer (BC) at the time of diagnosis with recurrence-free survival (RFS) and risk of bone-dominant metastases (BDM) in the I-SPY 1 trial (CALGB 150007/150012; ACRIN 6657). ( A4 )
Jiali Li , MD, PhD - University of California, San Francisco Helen Diller Family Comprehensive Cancer Center


Abstract # 143 : Intraoperative electron radiotherapy in early-stage breast cancer: A report on 226 patients. ( A5 )
Stefano dall'Oglio , MD - Radiation Oncology Department, University Hospital


Abstract # 144 : Reduced re-excisions while conserving tissue volume resected in DCIS patients. ( A6 )
Beth Cutler Freedman , M.D. - Beth Israel Medical Center


Abstract # 3 : Assessing the use of routine abdominal CT in staging evaluation of patients with primary breast cancer. ( A7 )
Stuart-Allison Moffat Staley , MD/MPH Candidate, BSPH - University of North Carolina School of Medicine


Abstract # 4 : Staging evaluation with bone scan, liver ultrasound, and chest radiograph in patients with primary breast cancer: A systematic review. ( A8 )
Stuart-Allison Moffat Staley , MD/MPH Candidate, BSPH - University of North Carolina School of Medicine


Abstract # 5 : Impact of the U.S. Preventive Services Task Force update for breast cancer screening on mammography utilization in women age 40 to 49. ( A9 )
Amy T. Wang , MD - Mayo Clinic


Abstract # 6 : Behavior of breast cancer in young women: A Surveillance Epidemiology and End Results (SEER) database review. ( A10 )
Anteneh A. Tesfaye , MD - McLaren Regional Medical Center


Abstract # 7 : Stratification of 5-year cancer detection rate in an organized breast screening program based on Gail model risk factors. ( B1 )
Rasika Rajapakshe , PhD - British Columbia Cancer Agency, Centre for the Southern Interior


Abstract # 8 : Gene expression panel (TheraPrint) analyzed as predictors of response to neoadjuvant chemotherapy (NCT) in patients (pts) with stage II-III and inflammatory breast cancer (BC). ( B2 )
George Somlo , MD - City of Hope


Abstract # 9 : Molecular subtyping using MammaPrint and BluePrint as an outcome predictor in U.S. breast cancer (BC) patients. ( B3 )
Katharine Yao , MD - NorthShore University HealthSystem


Abstract # 10 : Response and long-term outcomes after neoadjuvant chemotherapy: Pooled dataset of patients stratified by molecular subtyping by MammaPrint and BluePrint. ( B4 )
Stefan Gluck , MD - University of Miami Sylvester Comprehensive Cancer Center


Abstract # 11 : Central review of discordant samples for microarray based of ER, PR, and HER2 and local IHC/FISH assessment worldwide from 827 patients. ( B5 )
Jelle Wesseling , MD, PhD - Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital


Abstract # 145 : Evaluation of current consensus panel guidelines for APBI: A pooled analysis of William Beaumont Hospital and American Society of Breast Surgeons MammoSite registry trial data. ( B6 )
John Ben Wilkinson , MD - Oakland University William Beaumont School of Medicine, Beaumont Cancer Institute


Abstract # 146 : Impact of the number of cautionary/unsuitable risk factors on outcomes following accelerated partial breast irradiation. ( B7 )
Jessica Wobb, MD - Oakland University William Beaumont School of Medicine, Beaumont Cancer Institute


Abstract # 147 : Long-term outcome from RTOG 9517: A phase I/II study of accelerated partial breast irradiation (APBI) with mulitcatheter brachytherapy (MCT) following lumpectomy for early-stage breast cancer. ( B8 )
Julia R. White , MD - The Ohio State University Comprehensive Cancer Center


Abstract # 148 : Clinical efficacy of 2-day versus 5-day accelerated partial breast irradiation delivered via balloon-based brachytherapy: Results of a matched pair analysis. ( B9 )
Peter Y. Chen , MD, FACR - Oakland University William Beaumont School of Medicine, Beaumont Cancer Institute


Abstract # 149 : Accelerated partial breast irradiation using a strut-based brachytherapy device: A multi-institutional initial report on acute and late toxicity with greater than 24-month follow-up. ( B10 )
Jon F. Strasser , MD - Helen F. Graham Cancer Center - Christiana Care Health System


Abstract # 150 : Nomogram to predict sentinel lymph node involvement in patients with clinically node-negative breast cancer receiving neoadjuvant chemotherapy. ( B11 )
Lisa R. Allen , - University of Texas M. D. Anderson Cancer Center


Abstract # 151 : Trade-offs associated with axillary lymph node dissection: Implications of the eligibility versus enrollment in ACOSOG Z0011. ( B12 )
Monica Shalini Krishnan , M.D. - Harvard Radiation Oncology Program


Abstract # 152 : Surgical techniques, biomaterials, and patient variables that impact peri-operative nipple necrosis in nipple-sparing mastectomy. ( B13 )
Daniel J. Gould , MD,PhD - University of Texas M. D. Anderson Cancer Center


Abstract # 153 : The surgeon’s impact on ER status. ( B14 )
Kristin A. Skinner , MD, FACS - University of Rochester Medical Center


Abstract # 12 : Digital versus screen film mammography: Impact on positive predictive values following transition. ( B15 )
Elizabeth Roy , MD - Foothills Medical Centre


Abstract # 13 : Barriers to mammography among underserved women in a breast health center outreach program. ( B16 )
Oluwadamilola M. Fayanju , MD, MPHS - Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine


Abstract # 14 : Outcomes of an organized breast cancer screening program over the past 15 years. ( B17 )
Rasika Rajapakshe , PhD - British Columbia Cancer Agency, Centre for the Southern Interior


Abstract # 15 : The elderly breast cancer patient: Association of age, tumor size, and grade with sentinel lymph node status. ( B18 )
Meaghan Working O'Malley , MD - University of Michigan Comprehensive Cancer Center


Abstract # 16 : Immunohistochemical analysis of pathway HER2 4B5  performance in breast carcinoma expressing HER4. ( B19 )
Julie I Jay , Ph.D. - Ventana Medical Systems


Abstract # 17 : Breast cancer and vitamin D in postmenopausal minorities. ( C2 )
Demet Gokalp Yasar , MD - Rosalind Franklin University of Medicine and Science


Abstract # 18 : Analysis of interleukin-8, alpha1-antitrypsin and tumor necrosis factor-alpha as biomarkers of breast cancer in women of northeastern Mexico. ( C3 )
Miguel Angel Reyes-Lopez , PhD - Instituto Politécnico Nacional, Centre for Genomic Biotechnology


Abstract # 19 : Association of dyslipidemia with the aggressive molecular subtypes and pathologic profile of newly diagnosed nonmetastatic breast cancer patients. ( C4 )
Herdee Gloriane Cristal Luna , M.D. - National Kidney and Transplant Institute


Abstract # 20 : Characteristics of medullary breast carcinoma compared with invasive ductal carcinoma. ( C5 )
Inhye Park , - Division of Breast and Endocrine Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University, School of Medicine


Abstract # 21 : Are ulcerated breast cancers biologically more aggressive compared to their non-ulcerated counterparts? ( C6 )
Muy-Kheng Maria Tea , MD - Department of OB/GYN, Division of Senology, Medical University of Vienna


Abstract # 22 : Sentinella: Portable gamma camera versus conventional scintigram for intraoperative sentinel lymph node detection in breast cancer. ( C7 )
Debashis B. Ghosh , MS,FRCS,FEBS - Royal Free Hospital


Abstract # 24 : The usefulness of ultrasonography in a ductal carcinoma in situ screening program for Japanese woman. ( C9 )
Taijiro Kosaka , japan - Juntendo University School of Medicine


Abstract # 25 : Metformin and breast cancer risk: A meta-analysis and critical literature review. ( C10 )
Nananda Col , MD, MPP, MPH, FACP - University of New England


Abstract # 26 : Can excisional biopsy be avoided for papillary breast lesions with typical benign sonographic features and concordant core needle biopsy (CNB)? ( C11 )
Winnie Fu , MD - Foothills Medical Center


Abstract # 27 : Kinase activity signature of breast cancer using peptide phosphosensors. ( C12 )
Miki Mori , - Comprehensive Cancer Center, University of California, San Francisco


Abstract # 28 : Screening mammography in southeastern Kentucky: Is it a predictor of ongoing health disparities? ( C13 )
Raymond Elsoueidi , MD - Appalachian Regional Healthcare Cancer Center


Abstract # 29 : Breast cancer control in Iran: Specialized breast unit/national screening: Which one is the urgent priority? ( C14 )
Azadeh Joulaee , - Mahdieh Women's Hospital, Shahid Beheshti University of Medical Science


Abstract # 30 : Mutation analysis of PALB2 in high-risk and lower-risk patients negative for BRCA1 and BRCA2 mutations. ( C15 )
Shelly Cummings , MS - Myriad Genetic Laboratories, Inc.


Abstract # 31 : Identification of AGR3 as a potential biomarker though public genomic data analysis of triple-negative (TN) versus triple-positive (TP) breast cancer (BC). ( C16 )
Anita Umesh , PhD - NextBio


Abstract # 32 : Comparison of molecular (BluePrint and MammaPrint) and pathological subtypes for breast cancer among the first 800 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial. ( C17 )
Giuseppe Viale , MD - European Institute of Oncology


Abstract # 33 : Implications prognostics of methylation 14-3-3 sigma promoter in peripheral blood cell DNA  with nodal involvement status and tumor size for breast cancer patients. ( C18 )
Joaquina Martínez-Galán , MD, PhD - Medical Oncology Department, Hospital Universitario Virgen de las Nieves


Abstract # 34 : SIRT1 against breast cancer through downregulating Bcl-2 protein. ( C19 )
Dar-Ren Chen , - Changhua Christian Hospital


Abstract # 35 : Early diagnostic value of survivin and its alternative splice variants in breast cancers. ( C20 )
Salma Khan , MBBS, PhD - Loma Linda University


Abstract # 36 : The relationship of breast density, BMI, and menopausal status in mammography and MRI. ( C21 )
Jennifer Chun , MPH - New York University Cancer Institute and Langone Medical Center


Abstract # 37 : Does lobular carcinoma in situ (LCIS) affect biology of future breast cancer? Surveillance Epidemiology and End Results (SEER) database review. ( C22 )
Anteneh A. Tesfaye , MD - McLaren Regional Medical Center


Abstract # 38 : Impact of breast cancer and BRCA mutations on thoughts and feelings of future pregnancies. ( C23 )
Ashley Henriksen Woodson , MS, CGC - University of Texas M. D. Anderson Cancer Center


Abstract # 39 : Prophylactic mastectomy: The role of risk aversion. ( C24 )
Laura Kruper , MD - City of Hope


Abstract # 40 : Statin use and the development of bone metastasis in breast cancer patients. ( D1 )
Gentry Teng King , MD - Albert Einstein Medical Center


Abstract # 41 : Incidence and survival among female breast cancer patients in the United States: An analysis from national registry data 2000-2009. ( D2 )
Huan Huang , PhD - Boston Health Economics, Inc.


Abstract # 42 : Clinical outcome of preoperative breast MRI for early-stage breast cancer. ( D3 )
Shadi E. Hamdan , MD - St. Elizabeth's Medical Center


Abstract # 43 : Radiation therapy after breast-conserving surgery: When are we missing the mark? ( D4 )
Mohammed Nassif , MD FRCS(C) - McGill University


Abstract # 44 : Papillary lesions of the breast: Can larger core needle biopsy samples identify patients who may avoid surgical excision? ( D5 )
Alice P. Chung , MD, FACS - Cedars-Sinai Medical Center


Abstract # 45 : Uptake of surgical prophylaxis in underserved, ethnic minority BRCA mutation carriers. ( D6 )
Heather R. Macdonald , MD - Keck School of Medicine, University of Southern California


Abstract # 46 : A program to increase use of chemoprevention for women with high-risk breast lesions. ( D7 )
Constance A. Roche , MSN, ANP-BC - Massachusetts General Hospital


Abstract # 47 : Comparison of immunohistochemistry (IHC) and quantitative RT-PCR: ER, PR, and HER2 receptor status. ( D8 )
Cindy Christopherson , - Celera Corporation


Abstract # 48 : Risk-reducing surgery by skin-sparing mastectomy (SSM) and immediate implant-based reconstruction with and without titanized meshes and quality of life. ( D9 )
Mahdi Rezai , MD - Breast Center Düsseldorf, Louis Hospital


Abstract # 49 : Presentation of contralateral axillary involvement from breast cancer. ( D10 )
Vanessa Leilani Prowler , M.D. - H. Lee Moffitt Cancer Center & Research Institute


Abstract # 50 : Molecular differences between normal breast epithelia, pure DCIS, and DCIS adjacent to invasion. ( D11 )
Marina Guvakova , Ph.D. - University of Pennsylvania


Abstract # 51 : Estimation of additional MRI resources needed in British Columbia for screening high-risk women for breast cancer. ( D12 )
Rasika Rajapakshe , PhD - British Columbia Cancer Agency, Centre for the Southern Interior


Abstract # 52 : ACE inhibitors/ARB and the risk of breast cancer recurrence after surgery in Japanese population: A pilot study. ( D13 )
Takeo Fujii , MD - St. Luke's International Hospital


Abstract # 53 : Factors influencing risk reduction surgery among BRCA mutation carriers: A qualitative analysis. ( D14 )
Rachael Brandt , MS, CGC - Lankenau Medical Center


Abstract # 54 : Does breast density affect the ability of MRI to detect mammographically occult cancers? ( D15 )
Beth Cutler Freedman , M.D. - Beth Israel Medical Center


Abstract # 55 : Metastatic breast cancer and the elderly: A single institution, retrospective review. ( D16 )
Michael Kidd , M.D., M.S. - Mayo Clinic


Abstract # 56 : Determination of breast density by bioimpedance. ( D17 )
Karina Bukhanov , MD,FRCPC - Marvelle Koffler Breast Centre, Mount Sinai Hospital; Timmins and District Hospital


Abstract # 57 : The follow-up sought after diagnosis of a BRCA-1 or BRCA-2 mutation. ( D18 )
Karinn Marie Chambers , MD - CMC, Levine Cancer Institute


Abstract # 58 : Single-duct nipple discharge: How concerned should we be? ( D19 )
Michelle E. Allan , M.B., B.Chir. - Watford General Hospital


Abstract # 59 : Breast cancer detection among Irish BRCA1 and BRCA2 mutation carriers. ( D20 )
Elaine Walsh , MB, BCh, BAO, MRCPI - Mater Misericordiae University Hospital


Abstract # 60 : Does atypical ductal hyperplasia require 6 months of postoperative surveillance? ( D21 )
Jennifer Kay Plichta , MD - Loyola University Health Systems


Abstract # 188 : Predictors of microinvasion and its prognostic role in ductal carcinoma in situ. ( D22 )
Gloria Sue , BA - Yale University


Abstract # 189 : Evaluation of autophagy as a therapeutic target for DCIS. ( D23 )
Virginia A. Espina , MS, MT - George Mason University


Abstract # 190 : The development of the DCIS score: Scaling and normalization in the Marin General Hospital cohort. ( D24 )
Frederick L. Baehner , MD - Genomic Health


Abstract # 191 : Higher tamoxifen use as chemoprophylaxis in patients with ductal carcinoma in situ (DCIS) in the last decade. ( D25 )
Erin E. Roesch , MD - Wexner Medical Center at The Ohio State University


Abstract # 192 : Indication of sentinel lymph node biopsy with breast-conserving surgery for ductal carcinoma in situ considering lymphatic flow. ( E1 )
Ayane Yamaguchi , MD - Department of Surgery, Osaka Red-Cross Hospital


Abstract # 193 : Experience and outcomes of nipple-sparing mastectomy following reduction mammoplasty. ( E2 )
Michael Alperovich , MD - New York University Medical Center


Abstract # 194 : Evaluation of one-step nucleic acid (OSNA) molecular assay for intra-operative diagnosis of sentinel lymph node metastasis. ( E3 )
Shramana Mitul Banerjee , MRCSed - Royal Free Hospital NHS Foundation Trust


Abstract # 195 : Clinical relevance of the use of FDG PET? CT in locally advanced breast cancer. ( E4 )
Marie-Jeanne TFD Vrancken Peeters , MD, PhD - Dutch Cancer Institute, NKI-AvL


Abstract # 196 : Novel surgical technique to selectively remove metastatic axillary lymph nodes in breast cancer patients after neoadjuvant chemotherapy: The MARI procedure—Marking of the axilla with radioactive iodine seeds. ( E5 )
Marie-Jeanne TFD Vrancken Peeters , MD, PhD - Dutch Cancer Institute, NKI-AvL


Abstract # 197 : Metronomic chemotherapy (MC) in the neoadjuvant setting: Results of two parallel feasibility trials in patients (pts) with HER2 positive (HER2+) and negative (HER2-) locally advanced breast cancer (LABC) (Traq-Me and TAME). ( E6 )
Vanessa Petry , MD - Instituto do Cancer do Estado de São Paulo, Universidade de São Paulo


Abstract # 198 : The dosimetric impact of supraclavicular nodal irradiation on the thyroid in patients receiving radiotherapy for breast cancer. ( E7 )
Kim Ann Ung , MBBS (Hons), BMedSc - Peter MacCallum Cancer Centre


Abstract # 199 : Extent of lymph node involvement in breast cancer patients with sentinel lymph node metastasis. ( E8 )
Takeshi Murata , MD - Department of Surgery, Keio University School of Medicine


Abstract # 200 : Axillary lymph node coverage of tangent radiotherapy: Comparison of supine versus prone positioning. ( E9 )
Gregory M. Thompson , MD - University of Cincinnati


Abstract # 201 : Feasibility of concurrent weekly paclitaxel and radiotherapy in node-positive breast cancer: An experience from India. ( E10 )
Mohan Kumar , - M.S. Ramaiah Medical College


Abstract # 202 : Adjuvant docetaxel and cyclophosphamide (DC) with prophylactic growth colony stimulating factor (GCSF) on days 8 and 12 in breast cancer patients: A retrospective analysis. ( E11 )
Rinat Yerushalmi , MD - Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel-Aviv University
 


  Poster Session B


Abstract # 61 : Making it work: Breast cancer survivorship care at Johns Hopkins. ( A1 )
Elissa Thorner Bantug , MHS - Johns Hopkins


Abstract # 62 : Risk of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) after adjuvant chemotherapy (CT) for early breast cancer (BC) in the community setting. ( A2 )
Neelima Denduluri , MD - Virginia Cancer Specialists, The US Oncology Network


Abstract # 63 : Socioeconomic and geographic disparities in immediate reconstruction after mastectomy in the United States. ( A3 )
Barbara A. Wexelman , MD MBA - St. Luke's Roosevelt Hospital


Abstract # 64 : Accrual of under-represented minority women to breast cancer clinical trials in Inland Empire, California. ( A4 )
Yuan Yuan , MD, PhD - Loma Linda University School of Medicine


Abstract # 65 : Acute care utilization (ACU) among women receiving adjuvant chemotherapy for early breast cancer (EBC). ( A5 )
Katherine Enright , MD MPH - Carlo Fidani Peel Regional Cancer Centre, Credit Valley Hospital


Abstract # 66 : Racial disparities in clinical presentation, treatment, and outcome of women with breast cancer: Analysis of national inpatient sample database. ( A6 )
Ahmed Dehal , MD, MPH - Arrowhead Regional Medical Center


Abstract # 67 : Perceived sexual dysfunction in breast cancer survivors. ( A7 )
Elizabeth Anne Block , MS III - Michigan State University College of Human Medicine


Abstract # 68 : Vascular toxicities of endocrine therapy in early-stage breast cancer: Encouraging observations in a nontrial setting. ( A8 )
Susan F. Dent , MD - Ottawa Hospital Cancer Centre


Abstract # 69 : Contralateral breast cancer: Effect of stage on survival after unilateral breast cancer. ( A9 )
Lori Uyeno , MD - City of Hope


Abstract # 102 : Effects of everolimus (EVE) on disease progression in bone and bone markers (BMs) in patients (pts) with bone metastases (mets). ( B1 )
Lowell L. Hart , MD, FACP - Florida Cancer Specialists


Abstract # 103 : Safety of everolimus in estrogen receptor–positive advanced breast cancer. ( B2 )
Alejandra T. Perez , MD - Memorial Cancer Institute


Abstract # 104 : Safety of everolimus for women over age 65 with advanced breast cancer (BC): 12.5-month follow-up of BOLERO-2. ( B3 )
Hope S. Rugo , MD - University of California, San Francisco Helen Diller Family Comprehensive Cancer Center


Abstract # 105 : Phase II randomized trial of toremifene 120 mg compared with exemestane 25 mg after prior nonsteroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive breast cancer. ( B4 )
Hirotaka Iwase , MD, PhD - Kumamoto University


Abstract # 106 : Triple-negative breast cancer (TNBC) and residual disease (non-pCR): Does size matter? ( B5 )
Peter Kern , MD - Breast Center Düsseldorf, Louis Hospital


Abstract # 107 : Improving the efficacy of chemotherapy drugs for the treatment of triple-negative breast cancers. ( B6 )
Behyar Zoghi , MD, PhD - University of Texas Health Science Center at San Antonio


Abstract # 108 : Efficacy of RAD001/carboplatin in triple-negative metastatic breast cancer: A phase II study. ( B7 )
Jasmeet Chadha Singh , MD - New York University Langone Medical Center


Abstract # 109 : Early efficacy analysis of the AE37 vaccine in patients with HER2 low-expressing and triple-negative breast cancer. ( B9 )
Elizabeth Ann Mittendorf , MD - University of Texas M. D. Anderson Cancer Center


Abstract # 82 : The effect of a varied exercise program (VEP) on shoulder function and lymphedema (LE) in breast cancer survivors (BCs): A pilot study. ( B10 )
Sophie Hanssens , MSc - UZ Brussel


Abstract # 83 : Comorbidity and outcomes after surgery among women with breast cancer: Analysis of national in-patient sample database. ( B11 )
Ahmed Dehal , MD, MPH - Arrowhead Regional Medical Center


Abstract # 84 : Re-assessment of surgical breast cancer quality indicators by the Florida Initiative for Quality Cancer Care (FIQCC) consortium. ( B12 )
Christine Laronga , MD - H. Lee Moffitt Cancer Center & Research Institute


Abstract # 85 : Time trends in survival in young women with breast cancer in a population-based study: Are there estrogen receptor status differentials? ( B13 )
Foluso Olabisi Ademuyiwa , MD, MPH - Roswell Park Cancer Institute


Abstract # 86 : Uptake and experiences of breast cancer patients referred for fertility preservation. ( B14 )
Jaime D Lewis , MD - H. Lee Moffitt Cancer Center & Research Institute


Abstract # 87 : A 5-year review of an educational program focused on meeting the needs of patients with advanced breast cancer. ( B15 )
Ivy A. Ahmed , MPH, MCHES - Cancer Support Community


Abstract # 88 : Patient informational needs about breast reconstruction post-mastectomy. ( B16 )
Ivy A. Ahmed , MPH, MCHES - Cancer Support Community


Abstract # 89 : The use of bioelectrical impedance spectroscopy (BIS) to detect subclinical changes potentially associated with the development of breast cancer-related lymphedema. ( B17 )
Frank Vicini , M.D., FACR - Michigan Healthcare Professionals, 21st Century Oncology


Abstract # 90 : Evaluation of a breast cancer survivorship clinic that uses a group medical appointment model: Patient program evaluation and financial analysis. ( B18 )
Kathy Trotter , DNP,RN, FNP-C - Duke Medicine


Abstract # 91 : Risk of skeletal-related events (SREs) in patients with breast cancer (BC) and newly diagnosed metastases to bone. ( B19 )
Charu Taneja , MPH - Policy Analysis Inc.


Abstract # 92 : Changing ER, PgR, and HER2 status between primary and recurrent breast cancer. ( C2 )
Akiko Matsumoto , - Department of Surgery, Keio University School of Medicine


Abstract # 93 : Male breast cancer: Overall survival in a single institution. ( C3 )
Anke Bergmann , Anke Bergmann - National Cancer Institute


Abstract # 94 : Breast cancer treatment and recurrence in octogenarians. ( C4 )
Adam Harris , MD - Mayo Clinic


Abstract # 95 : Proactive approach to risk reduction and early detection of breast cancer-related lymphedema. ( C5 )
Mei R. Fu , PhD, RN, ACNS-BC - New York University


Abstract # 96 : Outcome of rare types of breast cancer in Hispanic woman. ( C6 )
Saul Campos Gomez , MD - Instituto Nacional de Ciencias Medicas y Nutrición, Salvador Zubiran


Abstract # 97 : Incidence complications following sentinel lymph node biopsy or axillary lymph node dissection after breast cancer surgery. ( C7 )
Marcelo Adeodato Bello , Marcelo Bello - National Cancer Institute


Abstract # 133 : Long-term survivor (LTS) characteristics in HER2+ metastatic breast cancer (MBC). ( C8 )
Denise Aysel Yardley , MD - Sarah Cannon Research Institute/Tennessee Oncology, PLLC


Abstract # 134 : Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC). ( C9 )
Farrah Mikhail Datko , MD - Memorial Sloan-Kettering Cancer Center


Abstract # 135 : Trastuzumab-related cardiotoxicity among older breast cancer patients. ( C10 )
Mariana Chavez-Mac Gregor , MD, MSc - University of Texas M. D. Anderson Cancer Center


Abstract # 136 : Multiplex layered immunohistochemistry to predict response of HER2-positive breast cancer patients to trastuzumab therapy. ( C11 )
Soon Sik Park , PhD - 20/20 Genesystems, Inc.


Abstract # 137 : Correlation of quantitative p95HER2, HER2, and HER3 protein expression with pathologic complete response (pCR) in HER2-positive breast cancer patients (pts) treated with neoadjuvant chemotherapy and trastuzumab. ( C12 )
Jose Caetano Villasboas , MD - University of Miami Sylvester Comprehensive Cancer Center


Abstract # 138 : Sarcopenia to predict tolerance of adjuvant breast cancer chemotherapy. ( C14 )
Michael S. Sabel , MD - University of Michigan


Abstract # 139 : Optimizing breast cancer diagnosis in Kenya: Importance of standardization of technical methodologies for comparative breast cancer data. ( C15 )
Shahin Sayed , MD - Aga Khan University Hospital


Abstract # 140 : Single-institution experience with neoadjuvant chemotherapy for metaplastic breast cancer (MBC). ( C16 )
Anna Kaminsky , DO - University of Pittsburgh Medical Center


Abstract # 141 : Chemotherapy treatment patterns for early-stage breast cancer (ESBC): Decreasing use of anthracycline-based regimens. ( C17 )
Katherine M. Serrurier , - University of California, San Francisco Helen Diller Family Comprehensive Cancer Center


Abstract # 142 : Ki-67, p53, and clinical outcomes of patients with triple-negative breast cancer. ( C18 )
Yasuyuki Nishiyama , MD, PhD - Kumamoto City Hospital


Abstract # 154 : Long-term outcome after neoadjuvant radiochemotherapy in locally advanced noninflammatory breast cancer and predictive factors for a pathologic complete remission: Results of a multivariate analysis. ( C19 )
Christiane Matuschek , MD - University of Düsseldorf


Abstract # 155 : Age, hormone receptor status, ethnicity, and adjuvant radiation therapy as predictive factors for cancer-related death in patients age 70 and older with early-stage pT1a,b N0 breast cancer: An NCI-SEER database analysis. ( C20 )
Akkamma Ravi , MD - Weill Cornell Medical College, New York Hospital Queens


Abstract # 156 : Nipple-sparing subcutaneous mastectomy (NSSM) as dual-plane prosthetic reconstruction using the modified Wise pattern mastectomy, fasciocutaneous flap, and titan-polypropylen-mesh-interponation in women with macromastia. ( C21 )
Stefan Paepke , MD, PhD - Klinikum r.d. Isar Frauenklinik, Technische Universitaet Muenchen


Abstract # 157 : Skin dose effects of postmastectomy chest wall radiation therapy using brass mesh as an alternative to a bolus. ( C22 )
Erin Healy , MA - University of California, Davis School of Medicine


Abstract # 158 : Effect of IL-8 on integrin αvβ3 expression and cell motility via PI3K, Akt, and NF-κB-dependent pathway in human breast cells. ( C23 )
Nan Shao , - The First Affiliated Hospital, Sun Yat-Sen University


Abstract # 159 : Incidence of local recurrence in patients after breast-conserving surgery and postoperative radiotherapy with or without a supplementary radiation. ( C24 )
Danijela D. Scepanovic , MD, PhD - National Cancer Institute


Abstract # 160 : Estrogen receptor-positive, progesterone receptor-negative tumors: Pathology and outcome correlations from a single-center cohort. ( D1 )
Oana Cristina Danciu , MD - University of Illinois


Abstract # 161 : Subpectoral implants in oncoplastic-reconstructive breast surgery: Habit or necessity? ( D2 )
Stefan Paepke , MD, PhD - Klinikum r.d. Isar Frauenklinik, Technische Universitaet Muenchen


Abstract # 162 : Primary and secondary prophylactic nipple-sparing subcutaneous mastectomy (NSSM): A retrospective single-center analysis. ( D3 )
Stefan Paepke , MD, PhD - Klinikum r.d. Isar Frauenklinik, Technische Universitaet Muenchen


Abstract # 163 : Active targeting nanoparticle for breast cancer diagnosis and treatment. ( D4 )
Nobutaka Iwakuma , MD - Kurume University School of Medicine


Abstract # 164 : Will neoadjuvant chemotherapy affect the lymphatic routes to the sentinel lymph node? Investigation using indocyanine green fluorescence method. ( D5 )
Shigeru Tsuyuki , MD, PhD - Department of Surgery, Osaka Red-Cross Hospital


Abstract # 165 : Clinical and histopathologic tumor characteristics in patients with invasive breast carcinoma receiving metformin. ( D6 )
Nikola Besic , - Institute of Oncology


Abstract # 166 : Feasibility study of nipple sparing mastectomy for Japanese breast cancer patients. ( D7 )
Maiko Takahashi , MD - Department of Surgery, Keio University School of Medicine


Abstract # 167 : Comparison of long-term results of endoscopic video-assisted breast surgery (VABS) between trans-axillary retro-mammary appcoach (TARM) and periareolar approach. ( D8 )
Koji Yamashita , MD, PhD - Nippon Medical School


Abstract # 168 : Predictors of residual disease after breast-conserving surgery. ( D9 )
Sanjay Aneja , BS - Yale University School of Medicine


Abstract # 169 : Prediction of preclinical myocardial damage utilizing cardiac biomarkers and ultrasound myocardial tissue characterization by integrated backscatter in patients with breast cancer treated with postoperative adjuvant radiotherapy. ( D10 )
Yong Zhang , MD&PhD - Department of Surgical Oncology, First Affiliated Hospital of Medical School, Xi'an Jiaotong University


Abstract # 170 : In-breast tumor recurrence rate of breast CT-guided lumpectomy: A prospective multi-institutional study in Japan. ( D11 )
Nobuaki Sato , MD - Niigata Cancer Center Hospital


Abstract # 171 : Surgical treatment and outcome of patients with invasive breast carcinoma age 80 or older. ( D15 )
Nikola Besic , - Institute of Oncology


Abstract # 172 : Circulating CD68 positive (+) leukocytes in blood samples from patients (pts) with breast cancer (BC). ( D16 )
Maryam B. Lustberg , MD - The Breast Program, Ohio State University Comprehensive Cancer Center and the Stefanie Spielman Comprehensive Breast Center


Abstract # 173 : Experience with nipple-sparing mastectomy after prior whole-breast radiation. ( D17 )
Aimee Marlena Mackey , - Columbia University Medical Center


Abstract # 174 : KLF4 and ER as biomarkers for prognosis of breast cancer patients. ( D18 )
Takuya Nagata , MD - University of Toyama


Abstract # 175 : Postmastectomy radiation for stage ll breast cancer patients with T1/T2 lesions. ( D19 )
Shai Libson , MD - University of Miami School of Medicine


Abstract # 176 : Short-term outcomes of immediate breast reconstruction using implant or tissue expander after mastectomy in breast cancer patients. ( D20 )
Haekyung Lee , M.D - Department of Surgery, Kwandong University College of Medicine, Cheil General Hospital


Abstract # 177 : Pleomorphic lobular carcinoma in situ: A distinct entity of controversial significance. ( D21 )
Marina De Brot , MD PhD - Memorial Sloan-Kettering Cancer Center


Abstract # 178 : Hypofractionated breast irradiation in elderly cancer parients: A Brazilian pilot study. ( D22 )
Conceicao Souza Campos , MD,Phd - Hospital Haroldo Juacaba


Abstract # 180 : Axillary recurrence (AR) after negative sentinel node biopsy (SNB): Who is at risk? ( D24 )
Rachel Leah Farkas , MD - University of Rochester


Abstract # 179 : Tumor characteristics in obese women with breast cancer. ( D23 )
Jennifer Chun , MPH - New York University Cancer Institute and Langone Medical Center


Abstract # 181 : The CXCL7/CXCR2 axis and the migration of breast cells toward the malignant phenotype. ( D25 )
Mary Ann Kosr , MD, FACS - Wayne State University


Abstract # 182 : Clinical outcomes of patients with tumor bed-to-skin distance (TBS) ≤ 7mm treated with accelerated partial breast irradiation (APBI) using multilumen catheter. ( E3 )
Mirna Abboud , MD - The Methodist Hospital


Abstract # 183 : Radiation therapy for malignant phyllodes tumors: An analysis of over 3,100 patients from 1998 to 2009. ( E4 )
Richelle T. Williams , MD - University of Chicago


Abstract # 184 : Atypical vascular lesion after radiation therapy for breast cancer. ( E5 )
Ana Paula Refinetti , MD - New York University Langone Medical Center and New York University Cancer Institute


Abstract # 185 : Nipple-sparing mastectomy and subareolar biopsy: To freeze or not to freeze? ( E6 )
Michael Alperovich , MD - New York University Medical Center


Abstract # 186 : Intraoperative radiotherapy in previously augmented patients with early-stage breast cancer. ( E7 )
Dennis R. Holmes , M.D., F.A.C.S. - The Los Angeles Center for Women's Health


Abstract # 187 : Cost comparison of radiation treatment options after lumpectomy for breast cancer: Intraoperative radiotherapy versus alternatives. ( E8 )
Dennis R. Holmes , M.D., F.A.C.S. - The Los Angeles Center for Women's Health


Poster Session C


Abstract # 100 : Final overall survival (OS) and safety analyses of RIBBON-2, a randomized phase III trial of bevacizumab (BEV) versus placebo (PL) combined with second-line chemotherapy (CT) for HER2-negative BEV-naive metastatic breast cancer (MBC). ( A1 )
Adam M. Brufsky , MD, PhD - University of Pittsburgh Cancer Institute


Abstract # 70 : Improving cancer care by linking community cancer center physicians to breast cancer disease site-specific experts. ( A2 )
Patricia H. Hardenbergh , MD - Shaw Regional Cancer Center


Abstract # 71 : Rural and urban disparities in the evolution of sentinel lymph node utilization in breast cancer. ( A3 )
Amanda Kathleen Arrington , MD - City of Hope


Abstract # 72 : Health care utilization and costs associated with skeletal-related events (SREs) in patients with breast cancer (BC) and bone metastases (BMets). ( A4 )
May Hagiwara , PhD - Policy Analysis Inc.


Abstract # 73 : An overview of breast medical oncology documentation through the Florida Initiative on Quality Cancer Care (FIQCC): The Phase II 2009 results. ( A5 )
Jhanelle Elaine Gray , MD - H. Lee Moffitt Cancer Center & Research Institute


Abstract # 74 : Indirect costs associated with metastatic breast cancer. ( A6 )
Yin Wan , - Pharmerit International


Abstract # 75 : The impact of 5HT3RA antiemetics on the incidence of chemotherapy-induced nausea and vomiting (CINV), treatment adherence, and delay of therapy in early-stage breast cancer (BC) patients treated with moderately/highly emetogenic chemotherapy (MEC/HEC). ( A7 )
Hope S. Rugo , MD - University of California, San Francisco Helen Diller Family Comprehensive Cancer Center


Abstract # 76 : Web-based standard-regimen selection (SRS) and cancer-care registry (CCR) systems of a nationwide network in Japan: An attempt to improve breast cancer treatment. ( A8 )
Kazuhiko Sato , MD, PhD - Breast Oncology Center, Tokyo-West Tokushukai Hospital


Abstract # 79 : Using computerized decision support to improve compliance of cancer multidisciplinary meetings with evidence-based guidance. ( A11 )
Vivek Patkar , MS, MRCS - University College London


Abstract # 80 : Psycho-oncological screening in patients with newly diagnosed or relapsing breast cancer. ( A12 )
Meinolf Karthaus , MD - Klinikum Neuperlach


Abstract # 81 : Breast cancer patients' rights: How can they be respected in Iran? ( B1 )
Azadeh Joulaee , - Mahdieh Women's Hospital, Shahid Beheshti University of Medical Science


Abstract # 110 : Interim safety results of eribulin (E) combined with ramucirumab (RAM) in patients (pts) with advanced metastatic breast cancer (MBC). ( B2 )
Denise Aysel Yardley , MD - Sarah Cannon Research Institute/Tennessee Oncology, PLLC


Abstract # 111 : Patient-reported outcomes (PRO) in patients with metastatic breast cancer (MBC) from the VIRGO observational cohort study (OCS). ( B3 )
Peter Andrew Kaufman , MD - Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center


Abstract # 112 : Acute side effects of intraoperative electron radiotherapy of breast cancer. ( B4 )
Edwin Boelke , MD - University of Düsseldorf


Abstract # 113 : PIK3CA as a predictor of the clinical efficacy for epirubicin plus docetaxel neoadjuvant chemotherapy in breast cancer. ( B5 )
Xi Ru Li , - Division of Breast Surgery, Department of General Surgery, General Hospital of Chinese People's Liberation Army


Abstract # 114 : Phase II results of tasisulam-sodium in previously treated patients with metastatic breast cancer. ( B6 )
Lee Steven Schwartzberg , MD - ACORN Research and The West Clinic


Abstract # 115 : Efficacy and safety of metronomic chemotherapy with all-oral combination of low-dose etoposide/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes. ( B7 )
Yan Wei , - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University School of Oncology, Beijing Cancer Hospital and Institute


Abstract # 116 : Treatment patterns by lines of therapy in metastatic breast cancer: Evidence from a large insured population in the United States. ( B8 )
Saurabh Ray , Ph.D. - Abbott Laboratories


Abstract # 117 : Characterization of responders versus nonresponders to the anti-estrogen agent fulvestrant: A retrospective cohort study. ( B9 )
Santosh Bhusal , M.D. - Fairview Hospital


Abstract # 118 : Sonodynamic and photodynamic therapy in advanced refractory breast cancer. ( B10 )
Xiaohuai Wang , MD - Liu Hua Qiao Hospital


Abstract # 119 : Use of disseminated tumor cells to predict outcome in patients with stage I-III breast cancer. ( B11 )
Sarah Marie Gainer , MD - University of Texas M. D. Anderson Cancer Center


Abstract # 120 : Response of angiogenic factors to the treatment with melatonin in breast cancer cell lines. ( B12 )
Bruna Victorasso Jardim , MSc - Universidade Estadual Paulista


Abstract # 121 : Comparison of the incidence of peripheral neuropathy (PN) with eribulin versus ixabepilone (IXA) in metastatic breast cancer (MBC) patients: A randomized phase II study. ( B13 )
Linda T. Vahdat , MD - Weill Cornell Medical College


Abstract # 122 : Feasibility of two schedules of weekly paclitaxel as (neo)adjuvant treatment for patients (PTS) with HER2-negative breast cancer (BC) in the Brazilian community setting. ( B14 )
Iuri Amorim Santana , MD - Instituto do Cancer do Estado de São Paulo, Universidade de São Paulo


Abstract # 123 : Adjuvant chemotherapy for early-stage breast cancer: Choice of regimen and associated hematologic toxicities in a metropolitan Australian hospital. ( C1 )
Katherine Mary Lovat , MBBS - Gold Coast Hospital


Abstract # 124 : TS-1 and docetaxel followed by 5-FU/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer: A phase II study. ( C2 )
Tetsu Hayashida , MD, PhD - Department of Surgery, Keio University School of Medicine


Abstract # 125 : BOLERO-2: Health-related quality-of-life (HRQoL) in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane. ( C3 )
Hope S. Rugo , MD - University of California, San Francisco Helen Diller Family Comprehensive Cancer Center


Abstract # 126 : Factors associated with local control in inflammatory breast cancer. ( C4 )
Lindsay C. Brown , MD - Mayo Clinic


Abstract # 127 : Maximizing metastatic breast cancer therapy selection: Physician practice patterns and competence assessment. ( C5 )
Tina Boyd Stacy , PharmD, BCOP, CCMEP - Educational Concepts Group, LLC


Abstract # 128 : Characterization of the overall survival benefit in ENCORE 301, a randomized, placebo-controlled phase II study of exemestane with and without entinostat in ER+ postmenopausal women with metastatic breast cancer. ( C6 )
Pamela Klein , MD - PMK Consulting


Abstract # 129 : A review of clinical endpoints and use of quality-of-life outcomes in phase III metastatic breast cancer clinical trials. ( C7 )
Raman Tatla , MD Candidate - University of Toronto


Abstract # 130 : Targeting of endocrine therapy resistance through combined mTOR and histone deacetylase inhibition. ( C8 )
Peter Ordentlich , - Syndax Pharmaceuticals


Abstract # 131 : Neoadjuvant therapy (NAT) for breast cancer at the Odette Cancer Centre: What have we been doing and how do we compare? ( C9 )
Claudia Arce , MD - National Cancer Institute


Abstract # 132 : Thymidylate synthase expression as a predictive factor for response and progression-free survival in metastatic breast cancer patients. ( C10 )
Hirohito Seki , MD - Kitasato University Kitasato Institute Hospital